Research
Hormonal
Dual GLP1R/GIPR agonists label pancreatic beta, alpha, and delta cells with varying intensity (beta > alpha = delta), engaging distinct receptor nanodomains that differ from those targeted by single agonists.
Dual agonists affect multiple hormone-secreting cells in the pancreas, with the strongest effect on insulin-secreting beta cells, followed by glucagon-secreting alpha and somatostatin-secreting delta cells.
GoodSupportsHIGH confidence
daLUXendins label rodent and human pancreatic islet cells, with a signal intensity of β cells > α cells = δ cells... At the single-molecule level, daLUXendin targets endogenous GLP1R–GIPR nanodomains, which differ in organization and composition from those targeted by a single agonist.
Why this rating
High-resolution imaging (dSTORM, STED) in multiple cell types provides strong mechanistic evidence.
Source
Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain
Anne de Bray et al. · Nature Metabolism · 2025
DOI 10.1038/s42255-025-01342-6
mechanism_onlyCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →